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Introduction
A promising approach for cancer treatment involves the introduction of the herpes simplex virus type 1 (HSV-1) thymidine kinase (tk) gene into tumor cells, followed by the administration of the antiherpetic drug, ganciclovir. Due to its broad substrate specificity, HSV-1 tk is able to monophosphorylate ganciclovir, which is then further metabolized to its triphosphate form by cellular kinases. Triphosphorylated ganciclovir has a deleterious effect on DNA polymerization, resulting in tumor cell death. Complete regression of rat brain tumors was demonstrated after in situ retrovirally mediated transduction with the HSV-1 tk gene and subsequent treatment with ganciclovir. 1, 2 The feasibility of this combined gene/chemotherapy approach is currently evaluated in several clinical trials for the treatment of brain tumors, ovarian cancer and pleural mesothelioma. 3 In addition to GCV, a variety of purine and pyrimidine nucleoside analogues were shown to exert high cytostatic activities against tumor cells transfected with the thymidine kinase genes of either HSV-1, HSV-2 or varicella-zoster virus.
tk gene in all the cells of a tumor. [10] [11] [12] Therefore, the success of the combined gene/chemotherapeutic approach heavily depends on the so-called bystander effect, 1 ie the killing of nontransfected bystander tumor cells by drug metabolites formed in nearby tk gene-transfected cells. Indeed, complete tumor eradication has been demonstrated even when as few as 10% of the tumor cell inoculum is transfected with the herpes tk gene. 1, 2, 13 Two explanations may account for this bystander effect. Freeman et al 13 showed by electron microscopic analysis that nontransfected tumor cells phagocytose apoptotic vesicles, containing phosphorylated ganciclovir metabolites derived from degenerating tk gene-transfected cells. However, the observation that bystander killing occurs even before the tk gene-transfected cells start to die and fragment, favors a model of metabolic cooperation, ie the transfer of phosphorylated ganciclovir metabolites through intercellular gap junctions. 14, 15 Bystander-insensitive tumor cell lines have been shown to express low levels of connexin-43, a major component of gap junctions. Transfection with the connexin-43 gene rendered these cells sensitive to bystander killing. 16, 17 Moreover, a close correlation was found between the extent of gap junctional intercellular coupling and in vitro bystander tumor cytotoxicity. 18, 19 There are several possibilities to enhance the bystander effect in herpes tk gene/chemotherapy. By upregulating connexin-43 expression and thus enhancing gap junctional intercellular coupling (GJIC), retinoic acid was able to increase bystander cell killing. 20 In this respect, it should be noted that GJIC is often down-regulated in tumors. 21 Another approach may be based on the identification of new nucleoside analogues that possess superior bystander killing capabilities. Therefore, we evaluated the ability of six pyrimidine and six purine nucleoside analogues, represented by (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and ganciclovir (GCV), respectively, to exert a bystander killing effect in vitro. The data reported here indicate that purine nucleoside analogues have a more pronounced bystander killer effect than pyrimidine nucleoside analogues. These findings were corroborated by autoradiography experiments that clearly showed that 2′-3 H-BVDU is much less efficiently incorporated than is 8-3 H-GCV in the nuclei of bystander cells.
Results
Inhibitory effect of the antiviral compounds on tumor cell proliferation Six pyrimidine nucleoside analogues (ie BVDU, S-BVDU, IVFAU, BVDC, BVaraU and araT) and six purine nucleoside analogues (ie GCV, E-GCV, LBV, PCV, BCV, ACV) ( Figure 1 ) were evaluated for their inhibitory effect on the proliferation of nontransfected (OstTK − ) and HSV-1 tk-GFP gene-transfected osteosarcoma cells. As shown in Table 1 , the pyrimidine nucleoside analogues were devoid of any inhibitory activity against OstTK − cells. IVFAU, BVDC and araT inhibited OstTK − cell proliferation only at concentrations above 200 m, while BVDU, S-BVDU and BVaraU showed 50% inhibitory concentrations (IC 50 values) up to 900 m. However, the pyrimidine nucleoside analogues became exquisitely inhibitory after transfection of the osteosarcoma cells with the HSV-1 tk-GFP fusion gene. S-BVDU and BVaraU exhibited comparable IC 50 values of 0.008 and 0.004 m, respect- + cell growth at concentrations ranging from 0.006 to 0.013 m, displaying selectivity indices up to 29 000. ACV had the lowest selectivity index (ie 1200) of all the guanosine derivatives that were evaluated.
Figure 1 Chemical structures of the pyrimidine and purine nucleoside analogues: (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU); (E)-5-(2-bromovinyl)-2′-deoxy-4′-thiouridine (S-BVDU); (E)-5-(2-iodovinyl)-2′-deoxy-2′-fluoro-1-␤-d-arabinofuranosyluracil (IVFAU); (E)-5-(2-bromovinyl)-2′-deoxycytidine (BVDC); (E)-5-(2-bromovinyl)-1-␤-d-arabinofuranosyluracil (BVaraU); 1-␤-d-arabinofuranosylthymine (araT); 9-(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir, GCV): the elaidic acid derivative of GCV (E-GCV); (R)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine (lobucavir, LBV, cyclobut-G, BMS-180194); 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (penciclovir, PCV); (R)-9-[(3,4-dihydroxybutyl)guanine] (buciclovir, BCV); 9-(2-hydroxyethoxymethyl)guanine (acyclovir, ACV).

Bystander effect: pyrimidine nucleoside analogues
The bystander effect implies that, in mixed (nontransfected and HSV-1 tk gene-transfected) cell cultures, nontransfected cells are killed after transfer of phosphorylated metabolites of the nucleoside analogues through intercellular gap junctions from nearby HSV-1 tk gene-transfected cells. 17, 18 The ability to exert such a bystander killing effect was evaluated for both the pyrimidine and purine nucleoside analogues. Results are depicted in Figures 2 and 3 . The dashed line in each graph depicts the theoretically calculated value for cell survival if no interaction between nontransfected and HSV-1 tk-GFP gene-transfected cells occurred, thus when no bystander effect was exerted. For example, a mixture of 75% HSV-1 tk-GFP gene-transfected cells and 25% nontransfected cells should give 25% cell survival after 3 days incubation in the presence of a lethal concentration of nucleoside analogue, as compared with control cell cultures without compound. Data shown are the means of at least three independent experiments. As is clear from Figure 2 , the pyrimidine nucleoside analogues exerted only a minor, if any, bystander killing effect at the concentrations tested (250, 50, 10 and 2 m). S-BVDU and BVaraU showed no bystander effect at all, whereas BVDU, IVFAU, BVDC and araT showed a minor bystander killing activity: at the highest concentration tested, that is at a Ͼ1000-fold higher concentration than required for 50% inhibition of cell proliferation, 25% and 50% HSV-1 tk-GFP gene-transfected cells in the tumor cell mixtures caused at most 60% and 90% cell killing, respectively ( Figure 2 ). This means that the death of one HSV-1 tk-GFP gene-transfected cell (due to the effect of the nucleoside analogue) was accompanied by the death of approximately one nontransfected bystander cell. When only 10% HSV-1 tk-GFP gene-transfected cells were present in the tumor cell mixture, the bystander effect was virtually absent with all pyrimidine nucleoside analogues. It should be noted that araT was slightly inhibitory to non-transfected OstTK − cells at all concentrations tested (see left end of the curves).
Bystander effect: purine nucleoside analogues In marked contrast with the pyrimidine nucleosides, GCV and most other purine nucleoside analogues showed a marked bystander killing effect ( Figure 3 ). Except for PCV, which displayed only a marginal bystander effect, all purine nucleoside analogues showed a concentration-dependent killer effect on the bystander cells. Ganciclovir at 50 m was able to kill as much as 65% and 75% of the cells in a tumor cell population that consisted of 5% and 10% tk gene-transfected cells, respectively. The killing of each gene-transfected cell was thus accompanied by the death of seven to 13 nontransfected (OstTK − ) bystander cells. E-GCV, which was recently shown to produce GCV metabolites with twoto three-fold longer intracellular half-life, 8 and BCV were almost equally effective as GCV. ACV showed a bystander killer effect only at the highest concentration tested (ie 50 m). LBV proved exquisitely effective in killing the bystander cells. This compound, at a concentration of 10 m, was approximately two-and three-fold more effective than GCV when the cell mixture contained only 5% and 10% gene-transfected cells, respectively. However, LBV at 50 m inhibited the growth of nontransfected cells by 40%. Only at the lowest concentration tested for GCV, E-GCV and LBV (0.5 and 0.2 m) the bystander effect was shown to be inefficient ( Figure 3) .
In this regard, it should be recognized that the compound concentrations applied in the bystander assay are not fully comparable with the IC 50 values found in the proliferation inhibition assays. Indeed, the compounds in the two assays were evaluated using an entirely different procedure, namely cell counting in the proliferation assay (a standard procedure for assaying inhibition of proliferation) and viability testing by determining mitochondrial dehydrogenase activity in a colorimetric assay for measuring the bystander effect. Furthermore, the incubation time used in both procedures, the initial cell number and the serum concentrations in the culture medium were different. The different experimental conditions may explain why LBV (50% inhibitory concentration of 18 m for inhibition of OstTK − cell proliferation) showed only 40% inhibition of OstTK − cell viability at 50 m in the bystander effect assay (Figure 3 ).
Autoradiography
Nontransfected OstTK
− cells, HSV-1 tk-GFP gene-transfected OstTK − cells, and a mixture of these cell cultures at a 3:1 ratio (all approximately 90% confluent, so that virtually all cells were in contact with other cells) were exposed to 2′-3 H-BVDU or H-GCV for 24 h and subsequently subjected to autoradiography as described in Materials and methods ( Figure 4 ). As expected, no appreciable radiolabel was detected in OstTK − cells (panels a and d). In contrast, the nuclei of OstTK 
Figure 4 Incorporation of 8-3 H-GCV (a, b, c) and 2′-3 H-BVDU (d, e, f) in tumor cell populations consisting of 100% OstTK − cells (a, d), 100% OstTK
Discussion
The bystander effect implies that nontransfected tumor cells are killed by neighboring herpes simplex virus thymidine kinase gene-transfected tumor cells upon treatment with antiviral nucleoside analogues. The importance of this bystander killing effect is reflected by the curative potential of intratumoral implantation of HSV-1 tk-expressing cells in situ and subsequent administration of GCV to the tumor-bearing animals or individuals. 13, 22, 23 In vivo, immunological rejection mechanisms and destruction of tumor blood vessels also seem to contribute to tumor eradication, [24] [25] [26] but experiments in immunocompromised animals unambiguously point to the crucial importance of the bystander effect in the in vivo setting. 19 The intraperitoneal infusion of tk genetransfected cells followed by GCV administration is currently under clinical investigation for the treatment of ovarian cancer. 22 Our experiments were performed in patient-derived thymidine kinase-deficient osteosarcoma tumor cells. Thymidine kinase deficiency is frequently observed in tumor cells, but does not markedly affect endogenous dTTP pool levels. Moreover, herpetic tk is only marginally susceptible to dTTP feedback inhibition. More importantly, cytosolic tk lacks any affinity for BVDU 27 and GCV, and thus, no major differences would be expected between tk-competent and tk-deficient tumor cells in terms of sensitivity of HSV-tk gene-transfected versus nontransfected cells.
The different pyrimidine nucleoside analogues (eg BVDU) exhibited a weak, if any, bystander effect in the in vitro colorimetric assay, regardless of their potent inhibitory potential against the HSV-1 tk-GFP gene-transfected tumor cells (Figure 2) . In sharp contrast, the majority of the purine nucleoside analogues displayed a pronounced bystander killing effect: cell killing in mixed (ie nontransfected and HSV-1 tk-GFP gene-transfected) tumor cell populations proved much higher than could be predicted from the nontransfected cell versus tk-GFP gene-transfected cell ratio (Figure 3) . These results were rather unexpected since the IC 50 values for tumor cell proliferation for the purine and the pyrimidine nucleoside analogues are similar (Table 1) . It should be noted that the results obtained for the pyrimidine nucleoside analogue BVaraU were rather puzzling (Figure 2) . It was expected that cell culture mixtures containing a certain amount of HSV-1 tk-GFP + cells gave absorbance values equal to (in absence of bystander killing) or lower than (in the case of bystander killing) the calculated values, after treatment with a lethal dose of BVaraU. Why the absorbance values were consistently higher than the calculated values is currently unclear and under further examination.
The reason for the striking difference in bystander killing potency of the pyrimidine versus purine nucleosides is presently unclear. However, some mechanistic features can be considered. One could simply hypothesize that purine nucleotides can travel more efficiently through gap junctions than pyrimidine nucleotides. Metabolic cooperation was initially demonstrated by Subak-Sharpe et al, 28, 29 who showed that hypoxanthine could only be incorporated in hypoxanthine/guanine phosphoribosyl transferase-deficient (HGPRT − and adenine phosphoribosyl transferase-deficient (APRT − ) cells, respectively. 31, 32 In addition to these three purine bases, two well-known second messengers (cGMP and cAMP), which are known to be able to be transferred to neighboring cells through gap junctions, are also purine nucleotides. 33 Recently, Bevans et al 33 showed connexin-specific selectivity among biological signaling molecules, while studying differential gap junction permeability for cAMP and cGMP. It was even found that cGMP was permeable through a substantially greater fraction of heteromeric gap junctions (connexin-32/connexin-26 channels) than was cAMP. Thus, some selectivity of cyclic guanine nucleoside monophosphate over cyclic adenine nucleoside monophosphate was observed. It may not be a coincidence that bystander effects have been predominantly or even exclusively described for purine nucleoside analogues, including the hypoxanthine, 6-thioguanine, 8-azaguanine and adenine derivatives (IMP, 6-thioGMP, 8-azaGMP and AMP, respectively), cAMP and cGMP, and now in this study a variety of acyclic and cyclic guanine nucleoside analogues. Gap junctions were thought to allow the transfer of any molecules less than 1000 kDa in molecular weight. However, Cao and coworkers 34 recently concluded from fluorescent dye transfer experiments with Cx32, Cx26 and Cx45 genetransfected cells that not molecular size but other molecular characteristics, such as charge determine gap junction permeability. Also, experimental data from Veenstra et al 35, 36 suggested a new gap junction model based on ionchannel interactions or electrostatic charge effects (as seen in multistate ion channels) rather than the conventional aqueous pore gap junction model. How the cells would discriminate between purine and pyrimidine nucleotides in this model is unclear.
Another hypothesis can also be envisioned. Since autoradiographic analysis of mixed tumor cell populations, exposed to 2′-3 H-BVDU or 8-3 H-GCV convincingly showed that 2′-3 H-BVDU is much less efficiently incorporated in DNA of nontransfected (bystander) tumor cells than 8-3 H-GCV (Figure 4) , it may be inferred that phosphorylated BVDU metabolites traverse the intercellular gap junctions between the transfected and nontransfected tumor cells to a much lesser extent than phosphorylated GCV metabolites. If we hypothesize that it is predominantly the monophosphorylated form of the nucleoside analogue that is transferred to bystander cells, the differential bystander effect of GCV and BVDU can be rationalised. GCV is monophosphorylated by HSV-1 tk, after which cellular kinases are responsible for further conversion to the di-and triphosphate form. Although mono-, di-and triphosphorylated GCV were found in wild-type cells cocultured with HSV-1 tk gene-transfected cells and treated with 3 H-GCV, 15 it could not be concluded which of the mono-, di-and/or triphosphate forms of GCV were channeled through the gap junctions to the nontransfected cells. Indeed, the di-and triphosphate forms of GCV found in the cocultured nontransfected cells could have been derived from transferred GCVmonophosphate upon the action of cellular nucleotide (nucleoside mono-and diphosphate) kinases. Alternatively, the monophosphate of GCV found in the nontransfected cells could have been produced from di-and triphosphorylated GCV through the action of cellular esterases and phosphatases.
BVDU has phosphorylation characteristics which entirely differ from GCV. After phosphorylation of BVDU to BVDU monophosphate, the latter is further converted by HSV-1 tk (and not cellular kinases) to the diphosphate form. Cellular NDP kinase then is responsible for the final conversion to BVDU triphosphate. Thus, the incorporation of BVDU in bystander cell DNA implicates the transfer of at least the diphosphate and/or the triphosphate form. Thus, if only monophosphorylated purine and pyrimidine nucleosides can travel through gap junctions to the neighboring nontransfected cells, BVDU can evidently not be incorporated in DNA of the bystander cells, because these cells lack the thymidylate kinase activity associated with the HSV-1 tk. In contrast, GCV-MP and the monophosphates of the other acyclic purine nucleoside analogues could easily further be metabolized in the nontransfected cells by cellular kinases and then exert their pronounced bystander effect. The hypothesis that predominantly nucleoside monophosphate metabolites can travel through gap junctions is also indirectly supported by the above-mentioned observations that the hypoxanthine, 6-thioguanine, 8-azaguanine and adenine derivatives (IMP, 6-thioGMP, 8-azaGMP and AMP), and also cAMP and cGMP are able to cross gap junctions. cAMP and cGMP are not further metabolized to the di-and triphosphorylated form, whereas it has been proven that adenine, 6-thioguanine, hypoxanthine and 8-azaguanine must be converted to the monophosphate by HGPRT or APRT to exert their bystander effect. Furthermore, IMP (upon its formation from hypoxanthine by HGPRT) is not further metabolized to IDP and ITP, and thus the bystander effect of hypoxanthine must likely result from the transfer of its monophosphate derivative.
In conclusion, we have demonstrated that purine nucleoside analogues (for example GCV) are endowed with a far more effective bystander killer effect than pyrimidine nucleoside analogues (for example BVDU) in the combined suicide gene/chemotherapy approach for cancer treatment. This phenomenon was not related to a greater or lesser potent inhibitory effect on the proliferation of the transfected tumor cells. Recent observations criticizing the conventional gap junction model based solely on size restriction, [34] [35] [36] are consistent with our hypothesis that gap junction might be differentially permeable to a variety of nucleotides. Purine nucleoside analogues may effectively cross the gap junctions once they have been converted to their monophosphate form (by the viral TK) and then exert their bystander killing effect.
As the bystander effect is crucial to the succes of herpes tk suicide gene therapy for cancer, the data suggest that purine nucleoside analogues are in this regard intrinsically better suited for clinical use than are pyrimidine nucleoside analogues.
Materials and methods
Cell culture
Human osteosarcoma cells deficient in cytosol TK (designated OstTK − ) were provided by Professor M Izquierdo (Universidad Autónoma de Madrid, Spain). All cells were maintained in MEM culture medium (Gibco, Paisley, UK), supplemented with 10% heat-inactivated fetal calf serum (FCS; Integro, Zaandam, The Netherlands), 2 mm l-glutamine (Gibco), 0.075% (w/v) NaHCO 3 (Gibco), 0.5 l/ml geomycine (Gentamycin, 40 mg/ml; Schering-Plough, Madison, NJ, USA) and 0.5 l/ml amphotericin B (Fungizone, 5 mg/ml; BristolMyers Squibb, Brussels, Belgium).
Compounds
The structural formulas of the test compounds are shown in Figure 1 . (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and (E)-5-(2-bromovinyl)-2′-deoxycytidine (BVDC) were synthesized by P Herdewijn and A Van Aerschot at the Rega Institute for Medical Research (Katholieke Universiteit Leuven, Leuven, Belgium). BVaraU was provided by H Machida (Yamasa Shoyu, Choshi, Japan). S-BVDU was provided by RT Walker (University of Birmingham, Birmingham, UK). IVFAU was synthesized by E Knaus and L Wiebe (University of Alberta, Alberta, Canada). AraT was from Sigma (St Louis, MO, USA), and also a kind gift from M Sandvold and F Myhren (Norsk Hydro, Porsgrunn, Norway). Ganciclovir (GCV) was from Syntex (Palo Alto, CA, USA). E-GCV was synthesized at Norsk Hydro. Lobucavir (cyclobut-G, LBV, BMS-180194) was from Bristol-Myers Squibb (Princeton, NJ, USA). Penciclovir (PCV) was obtained from I Winkler (Hoechst, Frankfurt, Germany). Acyclovir (ACV) was from Wellcome Research Laboratories (Research Triangle Park, NC, USA). Buciclovir (BCV) was from Astra Läkemedel (Sodertälje, Sweden).
Stable transfection of tumor cells
The construction of the HSV-1 tk-GFP (green fluorescent protein) vector has been described elsewhere. 37 Briefly, the PCR-amplified HSV-1 tk was inserted into the multiple cloning site of the pEGFP-N1 N-Terminal Protein Fusion Vector (Clontech, Palo Alto, CA, USA). The HSV-1 tk-GFP fusion construct was introduced into OstTK − cells via membrane fusion-mediated transfer using plasmid/liposome complexes (LipofectAMINE Reagent, Gibco), as described by the supplier. Stable transfectants were isolated by maintaining the cell cultures in the presence of HAT medium (ie normal growth medium, supplemented with 100 m hypoxanthine, 0.4 m aminopterin and 16 m thymidine). Monoclonal transfected cell lines were obtained by plating the cells at clonal density in tissue culture plates (Corning, NY, USA), after which single colonies were isolated and expanded. A standard FITC filter-equipped fluorescence microscope was used to ascertain HSV-1 tk-GFP fusion gene expression.
Inhibition of cell proliferation by antiherpetic compounds
To evaluate the inhibitory effect of antiviral nucleoside analogues on the proliferation of non-transfected and HSV-1 tk-GFP-expressing OstTK − cells, 7500 cells per well were plated in 96-well microtiter plates (Falcon, Becton Dickinson, Franklin Lakes, NJ, USA) and allowed to adhere. Cells were subsequently incubated at 37°C, in a humidified CO 2 -controlled atmosphere, in the presence of five-fold dilutions (in normal growth medium) of the compounds. After 3 days, the number of cells was counted in a Coulter Counter (Coulter Electronics, Harpenden, UK). The IC 50 was defined as the drug concentration required to inhibit cell proliferation by 50%.
Bystander effect
The procedure to evaluate the bystander effect of the compounds was modified from Park et al 20 as follows. OstTK − cells were mixed with HSV-1 tk-GFP gene-transfected cells in percentages ranging from 0 to 100% (0, 0.2, 1, 5, 10, 25, 50, 75, 90 and 100%) transfected cells. From these cell mixtures, 8400 cells per well were plated in 96-well microtiter plates (Falcon) and grown for 24 h at 37°C in a humidified CO 2 -controlled atmosphere. Growth medium containing 2% heat-inactivated fetal calf serum (FCS) was used. Cell mixtures were subsequently incubated in the presence of five-fold dilutions (in 2% FCScontaining medium) of the compounds. After 3 days, ie the time needed by untreated cell cultures to reach confluency, the viable cell number was assessed using the Cell Titer 96 Aqueous Non-radioactive MTT Cell Proliferation Assay (Promega, Madison, WI, USA). After 2.5 h incubation at 37°C, absorbance was measured at 490 nm. Preliminary experiments were performed to ascertain that absorbance increased linearly with increasing cell number, as monitored by a Coulter Counter.
Autoradiography
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